Phillipe Lutz joins Telormedix
pharmafile | May 13, 2010 | Appointment | Research and Development | appointment, research and development, telormedix
Swiss clinical stage biopharmaceutical company Telormedix has appointed Phillipe Lutz chief financial officer.
He joins the company from Synosia Therapeutics, where he chief financial officer for the last two years.
While at Synosia Therapeutics, he helped the company close a CHF32 million Series B financing round, which was ranked as the largest private Swiss biotech financing in 2008.
Prior to Synosia, he worked for nine years at Credit Suisse in Zurich contributing to a broad range of equity market transactions, including a number of IPOs, and rising to VP of the global markets solutions group.
“Philippe brings with him considerable knowledge and strength in the areas of financial and commercial development, a crucial addition to the leadership team as Telormedix steps up to the demands of clinical programmes,” said Dr Johanna Holldack, chief executive of Telormedix.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






